GARDNER, Mass., March  26, 2026  (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries,

POCI

Precision Optics Corporation, Inc. Announces Proposed Public Offering of Common Stock

Precision Optics Initiates Public Offering Amid Growth Focus

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>GARDNER, Mass., March  26, 2026  (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Precision Optics Corporation is launching an underwritten public offering of common stock, aiming to capitalize on market conditions. This initiative follows their strategic role in the medical and defense industries, potentially enhancing funding for growth opportunities.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>POCI initiates an underwritten public offering of common stock.</li><li>The offering is subject to market conditions and timelines are uncertain.</li><li>Lucid Capital Markets is the book-running manager for the offering.</li><li>The offering follows a SEC registration filed in June 2024.</li><li>POCI focuses on advanced optical instruments for healthcare and defense sectors.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Lucid Capital Markets (N/A)</strong>: Acting as the sole book-running manager for POCI&#039;s offering.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement fits into the &#039;Corporate Developments&#039; category, indicating POCI&#039;s financial maneuvers to support its growth, particularly in capital-intensive markets like healthcare and defense.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Market conditions surrounding the offering may affect stock performance.</li><li>Potential dilution could negatively impact existing shareholder value.</li><li>Success in the offering may provide necessary capital for growth initiatives.</li><li>Investor sentiment around the defense and healthcare sectors will influence POCI&#039;s stock.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>POCI is a designer of optical instruments for medical and defense sectors.</li><li>The public offering is based on an SEC shelf registration filed on June 7, 2024.</li><li>Lucid Capital Markets will manage the current stock offering.</li><li>The offering terms, including size and pricing, remain uncertain.</li><li>POCI&#039;s technologies are key in enhancing surgical and defense applications.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a cautious stance on POCI as the offering may dilute shares in the short term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">GARDNER, Mass., March  26, 2026  (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/POCI">POCI</a>), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>  <p align="justify">Lucid Capital Markets is acting as the sole book-running manager for the offering.</p>  <p align="justify">The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-280047) filed with the Securities and Exchange Commission ("SEC") on June 7, 2024, as amended on June 11, 2024, and declared effective by the SEC on June 14, 2024.</p>  <p align="justify">A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.</p>  <p align="justify">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.</p>  <p align="justify"><strong>About Precision Optics Corporation</strong><br></br></p>  <p align="justify">Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division&#39;s high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power.</p>  <p align="justify"><strong>Forward-Looking Statements:</strong></p>  <p align="justify">This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, without limitation, the Company's ability to complete an offering and the timing of any offering. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.</p>  <p align="justify"><strong>Company Contact:</strong><br></br>PRECISION OPTICS CORPORATION<br></br>22 East Broadway<br></br>Gardner, Massachusetts 01440-3338<br></br>Telephone: 978-630-1800</p>  <p align="justify"><strong>Investor Contact:</strong><br></br>LYTHAM PARTNERS, LLC<br></br>Robert Blum<br></br>Telephone: 602-889-9700<br></br>poci@lythampartners.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTM4MSM3NTA2MDYyIzIwMjQ1NDQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YWNlZTkwNDMtMTY0Yi00Yjg5LTgyZGUtNDQ4ZjQyN2RiYWM5LTEwMzYxMTYtMjAyNi0wMy0yNi1lbg==/tiny/Precision-Optics-Corporation.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/6d86ce33-7e41-41e5-90b0-1c74cd89785e"><img src="https://ml.globenewswire.com/media/6d86ce33-7e41-41e5-90b0-1c74cd89785e/small/precision-optics-logo-jpg.jpg" border="0" width="150" height="77" alt="Primary Logo"></img></a></p>

Precision Optics Corporation is launching an underwritten public offering of common stock, aiming to capitalize on market conditions. This initiative follows their strategic role in the medical and defense industries, potentially enhancing funding for growth opportunities.

Precision Optics Corporation, Inc. Announces Proposed Public Offering of Common Stock

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News